The giant cell arteritis (GCA) drug market is experiencing significant growth due to the increasing prevalence of GCA and advancements in treatment options. GCA, a chronic autoimmune condition that causes inflammation in the blood vessels, particularly the arteries in the head, is more commonly seen in older populations, with incidence rates increasing with age. Recent advancements in biologics and targeted therapies have improved the management of this condition, offering more effective treatment options. Drugs such as tocilizumab, an interleukin-6 receptor antagonist, have shown promising results in reducing inflammation and preventing complications such as vision loss, which is a major risk of untreated GCA. In addition, Janus kinase (JAK) inhibitors, such as upadacitinib and baricitinib, are emerging as novel therapies that provide an alternative to traditional corticosteroids, which often come with long-term side effects. The approval of new therapies, alongside early diagnosis through blood tests and imaging, is contributing to better patient outcomes. The market is expected to grow as more innovative treatments become available and awareness of the condition increases. North America dominates the market, while Asia-Pacific is projected to witness the highest growth due to improving healthcare infrastructure.
